Hostname: page-component-8448b6f56d-dnltx Total loading time: 0 Render date: 2024-04-24T04:16:39.026Z Has data issue: false hasContentIssue false
  • English
  • Français

Evaluation of the Effect of Treatment of Latent Tuberculosis Infection on QuantiFERON-TB Gold Assay Results

Published online by Cambridge University Press:  02 January 2015

Nira R. Pollock ,
Suely S. Kashino ,
Danielle R. Napolitano ,
Alex Sloutsky ,
Swati Joshi ,
Jasmine Guillet ,
Michael Wong ,
Edward Nardell  and
Antonio Campos-Neto
Nira R. Pollock*
Affiliation:
Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston
Suely S. Kashino
Affiliation:
Department of Cytokine Biology, Forsyth Institute, Boston
Danielle R. Napolitano
Affiliation:
Department of Cytokine Biology, Forsyth Institute, Boston
Alex Sloutsky
Affiliation:
Massachusetts State Laboratory Institute, Boston
Swati Joshi
Affiliation:
Massachusetts State Laboratory Institute, Boston
Jasmine Guillet
Affiliation:
Massachusetts State Laboratory Institute, Boston
Michael Wong
Affiliation:
Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston
Edward Nardell
Affiliation:
Division of Social Medicine and Health Inequalities, Brigham and Women's Hospital, Boston
Antonio Campos-Neto
Affiliation:
Department of Cytokine Biology, Forsyth Institute, Boston Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts
*
Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Lowry Medical Building, 110 Francis Street, Suite GB, Boston, MA 02215 (npollock@bidmc.harvard.edu)
Get access Rights & Permissions [Opens in a new window]

Abstract

To evaluate the utility of the QuantiFERON-TB Gold assay for monitoring latent tuberculosis treatment efficacy, the assay was performed serially for healthcare workers receiving isoniazid therapy. After 9 months of isoniazid therapy, all of these healthcare workers remained QuantiFERON-TB Gold positive, and cellular proliferation assays revealed persistently strong purified protein derivative responses. These results do not support the use of the QuantiFERON-TB Gold assay to monitor therapy.

Type
Concise Communication
Information
Infection Control & Hospital Epidemiology , Volume 30 , Issue 4 , April 2009 , pp. 392 - 395
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Mazurek, GH, Jereb, J, Lobue, P, Iademarco, MF, Metchock, B, Vernon, A. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005;54(RR-15):49–55.Google ScholarPubMed
2.Jensen, PA, Lambert, LA, Iademarco, MF, Ridzon, R. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep 2005;54:1–141.Google ScholarPubMed
3. QuantiFERON-TB Gold [package insert]. Document no. 05980000C. Victoria, Australia: Cellestis; 2006.Google Scholar
4.Napolitano, DR, Pollock, N, Kashino, SS, Rodrigues, V JrCampos-Neto A. Identification of Mycobacterium tuberculosis ornithine carboamyltransferase in urine as a possible molecular marker of active pulmonary tuberculosis. Clin Vaccine Immunol 2008;15:638–643.CrossRefGoogle ScholarPubMed
5. Public Health Agency of Canada. International tuberculosis incidence rates. March 31, 2008. Available at: http://www.phac-aspc.gc.ca/tbpc-latb/itir_e.html. Accessed September 1, 2008.Google Scholar
6.Wilkinson, KA, Kon, OM, Newton, SM, et al.Effect of treatment of latent tuberculosis infection on the T cell response to Mycobacterium tuberculosis antigens. J Infect Dis 2006;193:354–359.CrossRefGoogle Scholar
7.Chee, CB, KhinMar, KW, Gan, SH, Barkham, TM, Pushparani, M, Wang, YT. Latent tuberculosis infection treatment and T-cell responses to Mycobacterium tuberculosis–specific antigens. Am J Respir Crit Care Med 2007;175:282–287.CrossRefGoogle ScholarPubMed
8.Ewer, K, Millington, KA, Deeks, JJ, Alvarez, L, Bryant, G, Lalvani, A. Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. Am J Respir Crit Care Med 2006;174:831–839.CrossRefGoogle ScholarPubMed
9.Pai, M, Joshi, R, Dogra, S, et al.Persistently elevated T cell interferon-γ responses after treatment for latent tuberculosis infection among health care workers in India: a preliminary report. J Occup Med Toxicol 2006;1:7.CrossRefGoogle ScholarPubMed
10.Higuchi, K, Harada, N, Mori, T. Interferon-γ responses after isoniazid chemotherapy for latent tuberculosis. Respirology 2008;13:468–472.CrossRefGoogle ScholarPubMed
11.Goletti, D, Parracino, MP, Butera, O, et al.Isoniazid prophylaxis differently modulates T-cell responses to RD1-epitopes in contacts recently exposed to Mycobacterium tuberculosis: a pilot study. Respir Res 2007;8:5.CrossRefGoogle ScholarPubMed